Progressing a GPR65-Targeted Drug to the Clinic to Treat Cancer
Time: 3:00 pm
day: Conference Day Two
Details:
- Advancing to phase I/II clinical trials with a novel immune-oncology therapy
- What has been learned from GPCR clinical trials to drive therapeutic success and inform better trail designs?
- Addressing challenges in clinical trials through molecular-level discoveries to enable more precise targeting
